Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01127087
Other study ID # 10-000676
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received May 14, 2010
Last updated November 21, 2012
Start date May 2010
Est. completion date October 2011

Study information

Verified date November 2012
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Hypothesis: Oral administration of the oxalate metabolizing enzyme Oxazyme (OC4) will degrade food-borne oxalate and hence prevent its absorption from the gastrointestinal tract. In addition, by reducing oxalate concentrations in the gastrointestinal fluid, oxalate secretion from blood to the intestinal tract may be increased. Both effects would decrease blood levels of oxalate, and hence oxalate excretion in the urine.


Description:

Oxazyme is an oxalate degrading compound that can potentially degrade food-borne oxalate and hence prevent its absorption from the gastrointestinal tract.

We propose a 20-patient open-label trial pilot study of one month of Oxazyme twice daily (1gm Oxazyme sachet dissolved in 150 ml water) among adult subjects with a history of calcium oxalate nephrolithiasis. Patients will be stratified into those with enteric hyperoxaluria after Roux-en-Y Gastric Bypass (RYGB, n=10) and those with idiopathic hyperoxaluria (n=10). The patients will perform two, 24-hour, urine collections immediately before starting Oxazyme and on the last two days of the treatment period.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date October 2011
Est. primary completion date September 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Roux-en-Y gastric bypass hyperoxaluric Calcium oxalate (CaOx) stone subjects or Idiopathic hyperoxaluric CaOx stone subjects

- Patients must have or had radio-opaque stones present on x-ray, or a history consistent with the passage of a stone or stone surgery or Extracorporeal Shock Wave Lithotripsy (ESWL) in the last 5 years.

- Hyperoxaluria Ox/Cr ratio =36 mg/g

- The patient must be able to provide written informed consent

- Patients must be able to urinate reliably into a collection vessel to measure urine volume.

- Patients may be taking drugs for the prevention of stone disease, including pyridoxine, thiazides, citrate supplements and allopurinol, as long as there have been no changes in these medications for at least 3 months

Exclusion Criteria:

- Primary hyperoxaluria patients

- Use of Oxadrop, Oxabsorb, or other therapies affecting oxalate absorption from the gut, other than stable doses of calcium.

- Subjects who are pregnant. Women of childbearing potential must have a negative pregnancy test prior to enrollment and must practice some form of birth control during the trial.

- Patients on an unstable dose of any other drugs for the prevention of stone disease (i.e., pyridoxine, citrate supplements. etc.). Patients should have been on a stable dose for at least 3 months prior to randomization.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Oxazyme
Oxazyme (registered trademark) is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase (OxDC). It is formulated to enzymatically degrade available dietary oxalate prior to its absorption. Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily.

Locations

Country Name City State
United States Mayo Clinic in Rochester Rochester Minnesota

Sponsors (2)

Lead Sponsor Collaborator
Mayo Clinic OxThera

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Urinary Oxalate Creatinine Ratio The urinary oxalate per creatinine ratio is expressed as mg/g. Paired t-test will be used when comparing reduction of urinary oxalate resulting from treatment (versus baseline) for each subject group. Baseline, Week 4 No
Secondary Total Urinary Oxalate Excretion Oxalate is a salt of oxalic acid produced by the body's metabolism and excreted in the urine, measured in this study in two, 24-hour, urine collections. Baseline, 4 weeks No
See also
  Status Clinical Trial Phase
Withdrawn NCT06138327 - A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria Phase 1
Completed NCT02547805 - Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days Phase 2
Completed NCT02289755 - Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria Phase 2
Completed NCT02038543 - Hydroxyproline Influence on Oxalate Metabolism Phase 1/Phase 2
Completed NCT03095885 - A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria N/A
Recruiting NCT02780297 - Prospective Research Rare Kidney Stones (ProRKS)
Not yet recruiting NCT05443932 - Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients Phase 4
Completed NCT04756024 - Reference Interval of Spot Urinary Oxalate to Creatinine Ratio in Children
Completed NCT02503345 - Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones Phase 2
Completed NCT00199459 - Proteomic Study of Urinary Stone Disease N/A
Completed NCT04119765 - Plasma Oxalate in Patient With Short Bowel
Completed NCT02404701 - Effect of Over-the-counter Dietary Supplements on Kidney Stone Risk N/A
Completed NCT00283387 - Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria Phase 2
Completed NCT00587041 - Use of Oral Probiotics to Reduce Urinary Oxalate Excretion Phase 1/Phase 2
Completed NCT04571359 - Spot Urine Oxalate to Creatinine Ratio and 24 Hours Urinary Oxalate
Withdrawn NCT00280215 - Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria Phase 3
Completed NCT00588120 - Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria Phase 1